Skip to main content
. 2021 Feb 18;13(4):860. doi: 10.3390/cancers13040860

Table 2.

Comparison between irAEs in mRCC patients treated with nivolumab or with nivolumab and ipilimumab.

irAEs Nivolumab Nivolumab + Ipilimumab Total
n % n % n %
Pneumonitis 3 9.1% 0 0.0% 5 6.9%
Colitis (diarrhea) 5 15.1% 0 0.0% 5 11.6%
Hepatitis 4 12.1% 3 30,0% 7 16.3%
Skin reactions 8 24.2% 1 10.0% 9 20.9%
Nephritis 0 0.0% 1 10.0% 1 2.3%
Arthralgia/myalgia 4 12.1% 0 0,0% 4 9.3%
Endocrine-related events 14 42.4% 6 60.0% 20 46.5%